ArticleContrast media & molecular imaging2017
Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.
Article in Contrast media & molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [Pharmaceutics · 2026Article
- Evaluating TcAs for Use in Biotechnology Applications.Biotech (Basel (Switzerland)) · 2025Article
- DOTATATE PET Imaging in Olfactory Neuroblastoma and Association with SSTR Expression.Journal of neurological surgery. Part B, Skull base · 2024Article
- Exploration of commercial cyclen-based chelators for mercury-197 m/g incorporation into theranostic radiopharmaceuticals.Frontiers in chemistry · 2024Article
- Simultaneous Imaging of Ga-DOTA-TATE and Lu-DOTA-TATE in Murine Models of Neuroblastoma.IEEE transactions on radiation and plasma medical sciences · 2023Article
- Article
- Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.Journal of personalized medicine · 2021Review
- Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Detection and therapy of neuroblastoma minimal residual disease using [EJNMMI research · 2021Article
- Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.Theranostics · 2021Article
- Phase I study of theJournal for immunotherapy of cancer · 2020Article
- PET/CT in pediatric oncology.American journal of nuclear medicine and molecular imaging · 2020Review
- Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.Journal of pediatric hematology/oncology · 2019Article
- An evaluationOncotarget · 2018Article
- IMMUNOHISTOCHEMICAL MARKERS AND SPECT/CT SOMATOSTATIN-RECEPTOR (99MTC-TEKTROTYD) UPTAKE IN WELL AND MODERATELY DIFFERENTIATED NEUROENDOCRINE TUMORS.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-receptor imaging and therapy with radiolabeled somatostatin analogs such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.